• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Advances in biomedical research >New approaches using genetic material as a control to tuberculosis.
【24h】

New approaches using genetic material as a control to tuberculosis.

机译：利用遗传物质控制结核病的新方法。

获取原文
获取原文并翻译 | 示例
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Messenger RNA (mRNA) is highly versatile, non-toxic molecule that is easy to produce and store, which can allow transient protein expression in all cell types. The safety aspects of mRNA-based treatments in gene therapy make this molecule one of the most promising active components of therapeutic or prophylactic methods. The use of mRNA as strategy for the stimulation of the immune system has been used mainly in current strategies for the cancer treatment but until now there is no tested mRNA as vaccine for infectious disease. We produced mRNA of heat shock protein of 65-kDa (Hsp65) from Mycobacterium leprae and showed that vaccination of mice with a single dose of 10 μg of naked mRNA-Hsp65 through intranasal route was able to induce protection against subsequent challenge with virulent strain of M. tuberculosis. In order to determine if antigen-presenting cells present in the lung are capable of capture the mRNA, labelled mRNA-Hsp65 was administered by intranasal route and then lung APCs were analyzed by flow cytometry. These experiments showed that after 30 minutes until 8 hours the populations of CD 11 c~+, CDllb~+ and CD19~+ cells were able to capture the mRNA. Taken together, our results showed a novel and promise strategy to control experimental tuberculosis.
机译：Messenger RNA（mRNA）是一种用途广泛，无毒的分子，易于生产和储存，可以在所有细胞类型中瞬时表达蛋白质。基因治疗中基于mRNA的治疗的安全性使得该分子成为治疗或预防方法中最有希望的活性成分之一。使用mRNA作为刺激免疫系统的策略主要用于当前的癌症治疗策略中，但是直到现在还没有经过测试的mRNA作为传染性疾病的疫苗。我们从麻风分枝杆菌中产生了65 kDa（Hsp65）的热休克蛋白mRNA，并显示通过鼻内途径单剂量接种10μg裸mRNA-Hsp65裸露的小鼠能够诱导针对随后的强毒株攻击的保护作用。结核分枝杆菌。为了确定存在于肺中的抗原呈递细胞是否能够捕获mRNA，通过鼻内途径施用标记的mRNA-Hsp65，然后通过流式细胞术分析肺APC。这些实验表明，在30分钟到8小时后，CD 11 c〜+，CDllb〜+和CD19〜+细胞群能够捕获mRNA。综上所述，我们的结果显示了一种控制实验性结核病的新颖且有希望的策略。

著录项

  • 来源
    《Advances in biomedical research》|2010年|p.426-430|共5页
  • 会议地点 Cambridge(GB);Cambridge(GB);Cambridge(GB);Cambridge(GB);Cambridge(GB);Cambridge(GB)
  • 作者

    JULIO CESAR CETRULO LORENZI; ANA PAULA FAVARO TROMBONE; rnCAROLINA DAMAS ROCHA; rnLUCIANA PREVIATO DE ALMEIDA; rnRICARDO LOUSADA; et al;

  • 作者单位

    Department of Biochemistry and ImmunologyrnFaculty of Medicine of Ribeirao PretornUniversity of Sao Paulo Av. Bandeirantes, 3900. Ribeirao Preto, SPrnBRAZIL;

    Department of Biochemistry and ImmunologyrnFaculty of Medicine of Ribeirao PretornUniversity of Sao Paulo Av. Bandeirantes, 3900. Ribeirao Preto, SPrnBRAZIL;

    Department of Biochemistry and ImmunologyrnFaculty of Medicine of Ribeirao PretornUniversity of Sao Paulo Av. Bandeirantes, 3900. Ribeirao Preto, SPrnBRAZIL;

    Department of Biochemistry and ImmunologyrnFaculty of Medicine of Ribeirao PretornUniversity of Sao Paulo Av. Bandeirantes, 3900. Ribeirao Preto, SPrnBRAZIL;

    Department of Biochemistry and ImmunologyrnFaculty of Medicine of Ribeirao PretornUniversity of Sao Paulo Av. Bandeirantes, 3900. Ribeirao Preto, SPrnBRAZIL;

    et al;

  • 会议组织
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 生物医学工程;
  • 关键词

    mRNA; Hsp65; Tuberculosis; Vaccine; Antigen-presenting cells; pcDNA3-Hsp65;

    机译：mRNA； Hsp65;结核;疫苗;抗原提呈细胞； pcDNA3-Hsp65;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号